Initiating Insulin Therapy in Type 2 Diabetes

Immediate Insulin Initiation Criteria

The American Diabetes Association recommends initiating insulin therapy immediately in type 2 diabetic patients with A1C ≥10% or blood glucose ≥300 mg/dL, regardless of complications or cardiovascular risk, and can often be tapered after 2 weeks to 3 months once glucotoxicity is reversed 1, 2
Insulin should be started without delay when A1C ≥10-12% with or without symptoms, as this indicates severe hyperglycemia requiring immediate intervention 1, 3, 4
Blood glucose ≥300-350 mg/dL on presentation is another criterion for immediate insulin initiation, reflecting severe hyperglycemia that necessitates prompt treatment 1, 3, 4
Symptomatic hyperglycemia, such as polyuria, polydipsia, and weight loss at any glucose level, also warrants immediate insulin therapy, as it signifies uncontrolled diabetes 1, 2, 4
Evidence of catabolism, including unexpected weight loss, is a critical indicator for starting insulin, highlighting the need to address metabolic decompensation 1
Ketonuria or ketosis suggesting profound insulin deficiency is a condition that requires immediate insulin initiation to prevent diabetic ketoacidosis 4

For patients with A1C ≥9% after 3 months of optimal oral therapy plus lifestyle modifications, insulin should be strongly considered, as the likelihood of achieving target glucose levels with oral monotherapy alone is low 2, 3, 4
Newly diagnosed patients with A1C ≥9% may benefit from starting combination therapy including insulin to prevent therapeutic inertia and achieve better glucose control 2, 4

For patients meeting immediate criteria, basal insulin should be started at 0.2-0.3 units/kg/day, typically 10-20 units, given once daily at bedtime, and metformin should be continued unless contraindicated 1, 2
Sulfonylureas should be discontinued to reduce hypoglycemia risk when initiating insulin therapy 5
Insulin should be titrated by 2-4 units every 3 days, targeting fasting glucose 80-130 mg/dL, and tapered after 2 weeks to 3 months once glucose normalizes, reducing by 10-20% every 3-7 days 1, 2

In patients with established complications and cardiovascular disease, the presence of these conditions does not change the A1C or glucose thresholds for insulin initiation, emphasizing the importance of achieving glucose control regardless of complication status 1
SGLT2 inhibitors should be added for patients with heart failure or CKD (eGFR 20-60) for cardiorenal protection, independent of glucose control, highlighting the multifaceted approach to managing high-risk patients 1
GLP-1 receptor agonists are preferred for advanced CKD (eGFR <30) due to lower hypoglycemia risk and cardiovascular benefits, underscoring the need for tailored therapy in patients with significant renal impairment 1

Therapeutic inertia is a primary barrier to appropriate insulin use, with many clinicians delaying insulin initiation despite clear indications, leading to prolonged exposure to hyperglycemia and worsening complications 4, 5, 6
Waiting for "failure" of multiple oral agents when A1C is already ≥10% delays necessary therapy, and assuming insulin is "last resort" therapy contradicts modern guidelines positioning insulin as appropriate first-line treatment for severe hyperglycemia 1, 2, 4

Recent evidence supports short-term intensive insulin therapy for newly diagnosed patients with A1C >9%, which rapidly normalizes glucose, relieves glucotoxicity, and can achieve remission rates of 42-66% at 1-2 years after insulin discontinuation 2

While on insulin therapy, patients should self-monitor fasting and 2-hour post-meal glucose daily, have weekly follow-up initially for dose titration and hypoglycemia assessment, and check A1C at 3 months to assess response 2
Education on hypoglycemia symptoms and keeping glucose tablets available is crucial for patient safety 2

Delaying insulin initiation when clearly indicated prolongs exposure to hyperglycemia, accelerates microvascular complications, worsens beta-cell dysfunction, and misses the window for potential beta-cell recovery with early intensive therapy 1, 2, 4, 6